What does pruning of the pulmonary arteries on imaging indicate, and how should it be evaluated and managed for possible pulmonary hypertension?

Pruning of Pulmonary Arteries: Clinical Significance and Management

Pruning of the pulmonary arteries on imaging indicates loss of distal small vessel volume and is a key radiologic marker of pulmonary hypertension, particularly pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), requiring systematic evaluation with echocardiography, ventilation/perfusion scanning, and right heart catheterization to confirm diagnosis and guide treatment.

What Pruning Represents

Pruning refers to the abrupt narrowing or tapering of peripheral pulmonary vessels with reduced visualization of distal small vessels on CT imaging 1. This represents:

• Histologic arterial remodeling with intimal and medial thickening in small pulmonary arteries 2
• Loss of small vessel volume (vessels <5mm² cross-sectional area) relative to total pulmonary arterial volume 3
• Progressive vascular obliteration that correlates with disease severity 4

Research demonstrates that CT-based vascular pruning directly correlates with histologic arterial remodeling (correlation coefficient -0.41, p<0.0001), validating it as a non-invasive indicator of pulmonary vascular pathology 2. Importantly, pruning is associated with worse cardiac index in CTEPH patients (R=0.51, p=0.04) 4.

Associated CT Findings

When pruning is present, look for these accompanying features of pulmonary hypertension 1:

• Central pulmonary artery dilatation (main PA diameter >29mm)
• Proximal arterial enlargement with increased fraction of blood in large arteries 3
• Increased arterial tortuosity (specific to arterial tree, not venous) 3, 4
• Right ventricular hypertrophy and enlargement
• Mosaic attenuation pattern due to variable lung perfusion

Diagnostic Algorithm

Step 1: Initial Echocardiographic Assessment

Echocardiography is the recommended first-line diagnostic test when pruning is identified 5, 6. Assess for:

• Elevated right ventricular systolic pressure
• Right ventricular dysfunction
• Right atrial enlargement

Step 2: Distinguish CTEPH from PAH

Ventilation/perfusion (V/Q) scanning is mandatory to differentiate these conditions 6:

• Multiple segmental perfusion defects → suspect CTEPH (Group 4 PH)
• Normal or subsegmental patchy defects → suspect PAH (Group 1 PH) or Group 5 conditions

This distinction is critical because CTEPH requires contrast CT pulmonary angiography and potential surgical intervention 6.

Step 3: Exclude Secondary Causes

Perform these tests systematically 6:

• High-resolution chest CT to exclude interstitial lung disease (Group 3 PH)
• Pulmonary function tests with DLCO
• Routine biochemistry, immunology, HIV testing, thyroid function
• Abdominal ultrasound for portal hypertension screening

Step 4: Hemodynamic Confirmation

Right heart catheterization remains the gold standard 7 to confirm:

• Mean pulmonary arterial pressure >20 mmHg
• Pulmonary artery wedge pressure ≤15 mmHg (precapillary PH)
• Pulmonary vascular resistance ≥3 Wood units

Clinical Significance for Prognosis

Pruning has prognostic implications beyond diagnosis:

• Predicts emphysema progression in smokers (0.11 percentage points/year faster progression per 1-SD increase in arterial pruning) 8
• Correlates with declining lung function (faster FEV1/FVC decline) 8
• Reflects disease severity through correlation with cardiac index 4

Management Pathway

Once pulmonary hypertension is confirmed with pruning:

1. Refer to PH expert center for definitive classification and treatment planning 6
2. For CTEPH: Evaluate for pulmonary endarterectomy via selective pulmonary angiography 6
3. For PAH: Initiate targeted therapy based on risk stratification, with current maximal therapy being four-drug combinations 9
4. Monitor disease progression using serial imaging and hemodynamic assessments

Critical Pitfalls to Avoid

• Do not rely on CT pulmonary angiography alone for CTEPH diagnosis—it may miss the diagnosis; V/Q scanning is essential 6
• Do not perform open or thoracoscopic lung biopsy in PAH patients—it is not recommended and carries significant risk 6
• Do not assume pruning equals PAH—systematic evaluation is required to distinguish between Group 1,3,4, and 5 PH, as treatment differs substantially

Pruning with venous changes (interlobular septal thickening, lymphatic dilatation) suggests pulmonary veno-occlusive disease or pulmonary venous hypertension rather than typical PAH 1, requiring different management considerations.